Vitamin D in acute kidney injury

Inflammation and Allergy - Drug Targets

Volumn 12, Issue 4, 2013, Pages 262-272

  Braun, Andrea B ^a   Christopher, Kenneth B ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute kidney injury; Critical care mortality; ICU; Vitamin D

Indexed keywords

CREATININE; FIBROBLAST GROWTH FACTOR 23; IMMUNOSUPPRESSIVE AGENT; PLACEBO; TOLL LIKE RECEPTOR; VITAMIN D;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADAPTIVE IMMUNITY; ARTICLE; BONE METABOLISM; CALCIUM HOMEOSTASIS; CHRONIC KIDNEY DISEASE; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERCALCEMIA; IMMUNE RESPONSE; INNATE IMMUNITY; KIDNEY FAILURE; MALNUTRITION; META ANALYSIS (TOPIC); MORTALITY; NONHUMAN; PHOSPHORUS HOMEOSTASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; SEPSIS; SYSTEMATIC REVIEW (TOPIC); VITAMIN D DEFICIENCY;

ACUTE KIDNEY INJURY; ANIMALS; HUMANS; SEPSIS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84882792710     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/18715281113129990044     Document Type: Article

References (124)

1. Holick, M. Vitamin D: photobiology, metabolism, mechanism of action, and clinical applications. In: Primer on the metabolic bone diseases and disorders of mineral metabolism, Favus, M., Ed. American Society for Bone and Mineral Research: Washington, DC, 2006; pp 129-137.
2. Holick, M. F. Resurrection of vitamin D deficiency and rickets. J. Clin. Invest., 2006, 116 (8), 2062-2072.
3. Wang, H.; Xia, N.; Yang, Y.; Peng, D. Q. Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials. Lipids Health Dis., 2012, 11, 42.
4. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. The National Academies Press: Washington, DC, 2011.
5. Holick, M. F.; Binkley, N. C.; Bischoff-Ferrari, H. A.; Gordon, C. M.; Hanley, D. A.; Heaney, R. P.; Murad, M. H.; Weaver, C. M. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 2011, 96 (7), 1911-1930.
6. Vieth, R. What is the optimal vitamin D status for health? Prog. Biophys. Mol. Biol., 2006, 92 (1), 26-32.
7. Dawson-Hughes, B.; Mithal, A.; Bonjour, J. P.; Boonen, S.; Burckhardt, P.; Fuleihan, G. E.; Josse, R. G.; Lips, P.; Morales-Torres, J.; Yoshimura, N. IOF position statement: vitamin D recommendations for older adults. Osteoporos. Int., 2010, 21 (7), 1151-1154.
8. National Osteoporosis Foundation: Clinical Updates. http://www.nof.org/sites/repos/nof/issues/issue25 (accessed 01/15/2013).
9. Bellomo, R.; Ronco, C.; Kellum, J. A.; Mehta, R. L.; Palevsky, P. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care, 2004, 8 (4), R204-212.
10. Mehta, R. L.; Kellum, J. A.; Shah, S. V.; Molitoris, B. A.; Ronco, C.; Warnock, D. G.; Levin, A. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care, 2007, 11 (2), R31.
11. Singbartl, K.; Kellum, J. A. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int., 2012, 81 (9), 819-825.
12. Bagshaw, S. M.; Laupland, K. B.; Doig, C. J.; Mortis, G.; Fick, G. H.; Mucenski, M.; Godinez-Luna, T.; Svenson, L. W.; Rosenal, T. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit. Care, 2005, 9 (6), R700-709.
13. Ricci, Z.; Cruz, D.; Ronco, C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney Int., 2008, 73 (5), 538-546.
14. Ali, T.; Khan, I.; Simpson, W.; Prescott, G.; Townend, J.; Smith, W.; Macleod, A. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J. Am. Soc. Nephrol., 2007, 18 (4), 1292-1298.
15. Ostermann, M.; Chang, R. W. Acute kidney injury in the intensive care unit according to RIFLE. Crit. Care Med., 2007, 35(8), 1837-1843; quiz 1852.
16. Xue, J. L.; Daniels, F.; Star, R. A.; Kimmel, P. L.; Eggers, P. W.; Molitoris, B. A.; Himmelfarb, J.; Collins, A. J. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J. Am. Soc. Nephrol., 2006, 17 (4), 1135-1142.
17. Weisberg, L. S.; Allgren, R. L.; Genter, F. C.; Kurnik, B. R. Cause of acute tubular necrosis affects its prognosis. The Auriculin Anaritide Acute Renal Failure Study Group. Arch. Intern. Med., 1997, 157 (16), 1833-1838.
18. Coca, S. G.; Yusuf, B.; Shlipak, M. G.; Garg, A. X.; Parikh, C. R. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am. J. Kidney Dis., 2009, 53 (6), 961-973.
19. Li, Y. C. Vitamin D regulation of the renin-angiotensin system. J. Cell Biochem., 2003, 88 (2), 327-331.
20. Ishani, A.; Xue, J. L.; Himmelfarb, J.; Eggers, P. W.; Kimmel, P. L.; Molitoris, B. A.; Collins, A. J. Acute kidney injury increases risk of ESRD among elderly. J. Am. Soc. Nephrol., 2009, 20 (1), 223-228.
21. Lo, L. J.; Go, A. S.; Chertow, G. M.; McCulloch, C. E.; Fan, D.; Ordonez, J. D.; Hsu, C. Y. Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int., 2009, 76 (8), 893-899.
22. Wald, R.; Quinn, R. R.; Luo, J.; Li, P.; Scales, D. C.; Mamdani, M. M.; Ray, J. G., Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA, 2009, 302 (11), 1179-1185.
23. Coca, S. G.; Singanamala, S.; Parikh, C. R. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int., 2012, 81 (5), 442-448.
24. Braun, A.; Chang, D.; Mahadevappa, K.; Gibbons, F. K.; Liu, Y.; Giovannucci, E.; Christopher, K. B. Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill. Crit. Care Med., 2011, 39 (4), 671-677.
25. Braun, A. B.; Gibbons, F. K.; Litonjua, A. A.; Giovannucci, E.; Christopher, K. B. Low serum 25-hydroxyvitamin D at critical care initiation is associated with increased mortality. Crit. Care Med., 2012, 40 (1), 63-72.
26. Venkatram, S.; Chilimuri, S.; Adrish, M.; Salako, A.; Patel, M.; Diaz-Fuentes, G. Vitamin D deficiency is associated with mortality in the medical intensive care unit. Crit. Care, 2011, 15 (6), R292.
27. Matthews, L. R.; Ahmed, Y.; Wilson, K. L.; Griggs, D. D.; Danner, O. K. Worsening severity of vitamin D deficiency is associated with increased length of stay, surgical intensive care unit cost, and mortality rate in surgical intensive care unit patients. Am. J. Surg., 2012, 204 (1), 37-43.
28. McKinney, J. D.; Bailey, B. A.; Garrett, L. H.; Peiris, P.; Manning, T.; Peiris, A. N. Relationship between vitamin D status and ICU outcomes in veterans. J. Am. Med. Dir. Assoc., 2011, 12 (3), 208-211.
29. Higgins, D. M.; Wischmeyer, P. E.; Queensland, K. M.; Sillau, S. H.; Sufit, A. J.; Heyland, D. K. Relationship of Vitamin D Deficiency to Clinical Outcomes in Critically Ill Patients. JPEN J. Parenter. Enteral. Nutr., 2012, 36(6), 713-720.
30. Arnson, Y.; Gringauz, I.; Itzhaky, D.; Amital, H. Vitamin D deficiency is associated with poor outcomes and increased mortality in severely ill patients. QJM, 2012, 105(7), 633-639.
31. Druml, W.; Schwarzenhofer, M.; Apsner, R.; Horl, W. H. Fat-soluble vitamins in patients with acute renal failure. Miner Electrolyte Metab., 1998, 24 (4), 220-226.
32. Pietrek, J.; Kokot, F.; Kuska, J. Kinetics of serum 25-hydroxyvitamin D in patients with acute renal failure. Am. J. Clin. Nutr., 1978, 31 (10), 1919-1926.
33. Braun, A. B.; Litonjua, A. A.; Moromizato, T.; Gibbons, F. K.; Giovannucci, E.; Christopher, K. B. Association of low serum 25-hydroxyvitamin D levels and acute kidney injury in the critically ill. Crit. Care Med., 2012, 40 (12), 3170-3179.
34. Leaf, D. E.; Waikar, S. S.; Wolf, M.; Cremers, S.; Bhan, I.; Stern, L. Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes. Clin. Endocrinol. (Oxf), 2013, [Epub ahead of print].
35. Fiaccadori, E.; Lombardi, M.; Leonardi, S.; Rotelli, C. F.; Tortorella, G.; Borghetti, A. Prevalence and clinical outcome associated with preexisting malnutrition in acute renal failure: a prospective cohort study. J. Am. Soc. Nephrol., 1999, 10 (3), 581-593.
36. Lowe, K. E.; Maiyar, A. C.; Norman, A. W. Vitamin D-mediated gene expression. Crit. Rev. Eukaryot. Gene Expr., 1992, 2 (1), 65-109.
37. Bouillon, R. Vitamin D: from photosynthesis, metabolism and action to clinical applications. In: Endocrinology. Jameson, J.; De Groot, L. Eds. Saunders Elsevier: Philadelphia 2010, Vol. 1, p 1089.
38. Bouillon, R.; Carmeliet, G.; Verlinden, L.; van Etten, E.; Verstuyf, A.; Luderer, H. F.; Lieben, L.; Mathieu, C.; Demay, M. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev., 2008, 29 (6), 726-776.
39. Holick, M. F. Vitamin D deficiency. N. Engl. J. Med., 2007, 357 (3), 266-281.
40. Nagpal, S.; Na, S.; Rathnachalam, R. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev., 2005, 26 (5), 662-687.
41. DeLuca, H. F. Overview of general physiologic features and functions of vitamin D. Am. J. Clin. Nutr., 2004, 80 (6 Suppl), 1689S-196S.
42. van Driel, M.; Koedam, M.; Buurman, C. J.; Roelse, M.; Weyts, F.; Chiba, H.; Uitterlinden, A. G.; Pols, H. A.; van Leeuwen, J. P. Evidence that both 1alpha,25-dihydroxyvitamin D3 and 24-hydroxylated D3 enhance human osteoblast differentiation and mineralization. J. Cell Biochem., 2006, 99 (3), 922-935.
43. Hewison, M.; Burke, F.; Evans, K. N.; Lammas, D. A.; Sansom, D. M.; Liu, P.; Modlin, R. L.; Adams, J. S. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J. Steroid Biochem. Mol. Biol., 2007, 103(3-5), 316-321.
44. Mahon, B. D.; Wittke, A.; Weaver, V.; Cantorna, M. T. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J. Cell Biochem., 2003, 89 (5), 922-932.
45. Heine, G.; Anton, K.; Henz, B. M.; Worm, M. 1alpha,25-dihydroxyvitamin D3 inhibits anti-CD40 plus IL-4-mediated IgE production in vitro. Eur. J. Immunol., 2002, 32 (12), 3395-404.
46. Adorini, L.; Penna, G.; Giarratana, N.; Roncari, A.; Amuchastegui, S.; Daniel, K. C.; Uskokovic, M. Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands. J. Steroid Biochem. Mol. Biol., 2004, 89-90 (1-5), 437-441.
47. Prie, D.; Friedlander, G. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system. Clin. J. Am. Soc. Nephrol., 2010, 5 (9), 1717-1722.
48. Liu, S.; Tang, W.; Zhou, J.; Stubbs, J. R.; Luo, Q.; Pi, M.; Quarles, L. D. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol., 2006, 17 (5), 1305-1315.
49. White, K. E.; Carn, G.; Lorenz-Depiereux, B.; Benet-Pages, A.; Strom, T. M.; Econs, M. J. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int., 2001, 60 (6), 2079-2086.
50. Zierold, C.; Darwish, H. M.; DeLuca, H. F. Identification of a vitamin D-response element in the rat calcidiol (25-hydroxyvitamin D3) 24-hydroxylase gene. Proc. Natl. Acad Sci. U S A, 1994, 91 (3), 900-902.
51. Isakova, T.; Xie, H.; Yang, W.; Xie, D.; Anderson, A. H.; Scialla, J.; Wahl, P.; Gutierrez, O. M.; Steigerwalt, S.; He, J.; Schwartz, S.; Lo, J.; Ojo, A.; Sondheimer, J.; Hsu, C. Y.; Lash, J.; Leonard, M.; Kusek, J. W.; Feldman, H. I.; Wolf, M. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA, 2011, 305 (23), 2432-2439.
52. Gutierrez, O. M.; Mannstadt, M.; Isakova, T.; Rauh-Hain, J. A.; Tamez, H.; Shah, A.; Smith, K.; Lee, H.; Thadhani, R.; Juppner, H.; Wolf, M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med., 2008, 359 (6), 584-592.
53. Leaf, D. E.; Wolf, M.; Waikar, S. S.; Chase, H.; Christov, M.; Cremers, S.; Stern, L. FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin. J. Am. Soc. Nephrol., 2012, 7 (8), 1217-1223.
54. Navaneethan, S. D.; Schold, J. D.; Arrigain, S.; Jolly, S. E.; Jain, A.; Schreiber, M. J. Jr. Simon, J. F.; Srinivas, T. R.; Nally, J. V. Jr. Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD. Am. J. Kidney Dis., 2011, 58 (4), 536-543.
55. Wolf, M.; Shah, A.; Gutierrez, O.; Ankers, E.; Monroy, M.; Tamez, H.; Steele, D.; Chang, Y.; Camargo, C. A. Jr. Tonelli, M.; Thadhani, R. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int., 2007, 72 (8), 1004-1013.
56. Nykjaer, A.; Dragun, D.; Walther, D.; Vorum, H.; Jacobsen, C.; Herz, J.; Melsen, F.; Christensen, E. I.; Willnow, T. E. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell, 1999, 96 (4), 507-515.
57. Levin, A.; Bakris, G. L.; Molitch, M.; Smulders, M.; Tian, J.; Williams, L. A.; Andress, D. L. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int., 2007, 71 (1), 31-38.
58. Li, Y. C. Renoprotective effects of vitamin D analogs. Kidney Int., 2010, 78 (2), 134-139.
59. Ravani, P.; Malberti, F.; Tripepi, G.; Pecchini, P.; Cutrupi, S.; Pizzini, P.; Mallamaci, F.; Zoccali, C. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int., 2009, 75 (1), 88-95.
60. Zhang, Y.; Kong, J.; Deb, D. K.; Chang, A.; Li, Y. C. Vitamin D receptor attenuates renal fibrosis by suppressing the reninangiotensin system. J. Am. Soc. Nephrol., 2010, 21 (6), 966-973.
61. Tan, X.; Li, Y.; Liu, Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J. Am. Soc. Nephrol., 2006, 17 (12), 3382-3393.
62. Makibayashi, K.; Tatematsu, M.; Hirata, M.; Fukushima, N.; Kusano, K.; Ohashi, S.; Abe, H.; Kuze, K.; Fukatsu, A.; Kita, T.; Doi, T. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am. J. Pathol., 2001, 158 (5), 1733-1741.
63. Kuhlmann, A.; Haas, C. S.; Gross, M. L.; Reulbach, U.; Holzinger, M.; Schwarz, U.; Ritz, E.; Amann, K. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am. J. Physiol. Renal Physiol., 2004, 286 (3), F526-533.
64. Zhang, Z.; Sun, L.; Wang, Y.; Ning, G.; Minto, A. W.; Kong, J.; Quigg, R. J.; Li, Y. C. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int., 2008, 73 (2), 163-171.
65. Alborzi, P.; Patel, N. A.; Peterson, C.; Bills, J. E.; Bekele, D. M.; Bunaye, Z.; Light, R. P.; Agarwal, R. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension, 2008, 52 (2), 249-255.
66. Gysemans, C. A.; Cardozo, A. K.; Callewaert, H.; Giulietti, A.; Hulshagen, L.; Bouillon, R.; Eizirik, D. L.; Mathieu, C. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology, 2005, 146 (4), 1956-1964.
67. Zipitis, C. S.; Akobeng, A. K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch. Dis. Child, 2008, 93 (6), 512-517.
68. Deluca, H. F.; Cantorna, M. T. Vitamin D: its role and uses in immunology. FASEB J., 2001, 15 (14), 2579-2585.
69. Zehnder, D.; Quinkler, M.; Eardley, K. S.; Bland, R.; Lepenies, J.; Hughes, S. V.; Raymond, N. T.; Howie, A. J.; Cockwell, P.; Stewart, P. M.; Hewison, M. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int., 2008, 74 (10), 1343-1353.
70. Wang, T. T.; Nestel, F. P.; Bourdeau, V.; Nagai, Y.; Wang, Q.; Liao, J.; Tavera-Mendoza, L.; Lin, R.; Hanrahan, J. W.; Mader, S.; White, J. H. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol., 2004, 173 (5), 2909-2912.
71. Watkins, R. R.; Yamshchikov, A. V.; Lemonovich, T. L.; Salata, R. A. The role of vitamin D deficiency in sepsis and potential therapeutic implications. J. Infect., 2011, 63 (5), 321-326.
72. Liu, P. T.; Stenger, S.; Li, H.; Wenzel, L.; Tan, B. H.; Krutzik, S. R.; Ochoa, M. T.; Schauber, J.; Wu, K.; Meinken, C.; Kamen, D. L.; Wagner, M.; Bals, R.; Steinmeyer, A.; Zugel, U.; Gallo, R. L.; Eisenberg, D.; Hewison, M.; Hollis, B. W.; Adams, J. S.; Bloom, B. R.; Modlin, R. L. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science, 2006, 311 (5768), 1770-1773.
73. Liu, P. T.; Stenger, S.; Tang, D. H.; Modlin, R. L. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J. Immunol., 2007, 179 (4), 2060-2063.
74. Gombart, A. F.; Borregaard, N.; Koeffler, H. P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25dihydroxyvitamin D3. FASEB J., 2005, 19 (9), 1067-1077.
75. Bhalla, A. K.; Amento, E. P.; Krane, S. M. Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell Immunol., 1986, 98 (2), 311-322.
76. Meehan, M. A.; Kerman, R. H.; Lemire, J. M. 1,25-Dihydroxyvitamin D3 enhances the generation of nonspecific suppressor cells while inhibiting the induction of cytotoxic cells in a human MLR. Cell Immunol., 1992, 140 (2), 400-409.
77. Jones, B. W.; Heldwein, K. A.; Means, T. K.; Saukkonen, J. J.; Fenton, M. J. Differential roles of Toll-like receptors in the elicitation of proinflammatory responses by macrophages. Ann. Rheum. Dis., 2001, 60 (Suppl 3), iii6-iii12.
78. Anders, H. J.; Banas, B.; Schlondorff, D. Signaling danger: toll-like receptors and their potential roles in kidney disease. J. Am. Soc. Nephrol., 2004, 15 (4), 854-867.
79. Kim, B. S.; Lim, S. W.; Li, C.; Kim, J. S.; Sun, B. K.; Ahn, K. O.; Han, S. W.; Kim, J.; Yang, C. W. Ischemia-reperfusion injury activates innate immunity in rat kidneys. Transplantation, 2005, 79 (10), 1370-1377.
80. Shigeoka, A. A.; Holscher, T. D.; King, A. J.; Hall, F. W.; Kiosses, W. B.; Tobias, P. S.; Mackman, N.; McKay, D. B. TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and independent pathways. J. Immunol., 2007, 178 (10), 6252-6258.
81. Wu, H.; Chen, G.; Wyburn, K. R.; Yin, J.; Bertolino, P.; Eris, J. M.; Alexander, S. I.; Sharland, A. F.; Chadban, S. J. TLR4 activation mediates kidney ischemia/reperfusion injury. J. Clin. Invest., 2007, 117 (10), 2847-2859.
82. Wolfs, T. G.; Buurman, W. A.; van Schadewijk, A.; de Vries, B.; Daemen, M. A.; Hiemstra, P. S.; van 'T Veer, C. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J. Immunol., 2002, 168 (3), 1286-1293.
83. Gregori, S.; Giarratana, N.; Smiroldo, S.; Uskokovic, M.; Adorini, L. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes, 2002, 51 (5), 1367-1374.
84. Gregori, S.; Casorati, M.; Amuchastegui, S.; Smiroldo, S.; Davalli, A. M.; Adorini, L. Regulatory T cells induced by 1 alpha,25-Dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol., 2001, 167 (4), 1945-1953.
85. Matheu, V.; Back, O.; Mondoc, E.; Issazadeh-Navikas, S. Dual effects of vitamin D-induced alteration of TH1/TH2 cytokine expression: enhancing IgE production and decreasing airway eosinophilia in murine allergic airway disease. J. Allergy Clin. Immunol., 2003, 112 (3), 585-592.
86. Cantorna, M. T.; Woodward, W. D.; Hayes, C. E.; DeLuca, H. F. 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J. Immunol., 1998, 160 (11), 5314-539.
87. Zhu, Y.; Mahon, B. D.; Froicu, M.; Cantorna, M. T. Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur. J. Immunol., 2005, 35 (1), 217-224.
88. Iho, S.; Kura, F.; Sugiyama, H.; Takahashi, T.; Hoshino, T. The role of monocytes in the suppression of PHA-induced proliferation and IL 2 production of human mononuclear cells by 1,25-Dihydroxyvitamin D3. Immunol. Lett., 1985, 11 (5-6), 331-336.
89. Reichel, H.; Koeffler, H. P.; Tobler, A.; Norman, A. W. 1 alpha,25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc. Natl. Acad Sci. U S A, 1987, 84 (10), 3385-3389.
90. Boonstra, A.; Barrat, F. J.; Crain, C.; Heath, V. L.; Savelkoul, H. F.; O'Garra, A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J. Immunol., 2001, 167 (9), 4974-4980.
91. Canning, M. O.; Grotenhuis, K.; de Wit, H.; Ruwhof, C.; Drexhage, H. A. 1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur. J. Endocrinol., 2001, 145 (3), 351-357.
92. Kinsey, G. R.; Sharma, R.; Huang, L.; Li, L.; Vergis, A. L.; Ye, H.; Ju, S. T.; Okusa, M. D. Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J. Am. Soc. Nephrol., 2009, 20 (8), 1744-1753.
93. Kinsey, G. R.; Huang, L.; Vergis, A. L.; Li, L.; Okusa, M. D. Regulatory T cells contribute to the protective effect of ischemic preconditioning in the kidney. Kidney Int., 2010, 77 (9), 771-780.
94. Murphy, T. J.; Ni Choileain, N.; Zang, Y.; Mannick, J. A.; Lederer, J. A. CD4+CD25+ regulatory T cells control innate immune reactivity after injury. J. Immunol., 2005, 174 (5), 2957-2963.
95. Mahajan, D.; Wang, Y.; Qin, X.; Zheng, G.; Wang, Y. M.; Alexander, S. I.; Harris, D. C. CD4+CD25+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J. Am. Soc. Nephrol., 2006, 17 (10), 2731-2741.
96. Wolf, D.; Hochegger, K.; Wolf, A. M.; Rumpold, H. F.; Gastl, G.; Tilg, H.; Mayer, G.; Gunsilius, E.; Rosenkranz, A. R. CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J. Am. Soc. Nephrol., 2005, 16 (5), 1360-1370.
97. Ferenbach, D. A.; Kluth, D. C.; Hughes, J. Regulatory T cells: a brake on ischemic injury or an active promoter of tissue healing? Kidney Int., 2009, 76 (7), 689-691.
98. Farias, A. S.; Spagnol, G. S.; Bordeaux-Rego, P.; Oliveira, C. O.; Fontana, A. G.; de Paula, R. F.; Santos, M. P.; Pradella, F.; Moraes, A. S.; Oliveira, E. C.; Longhini, A. L.; Rezende, A. C.; Vaisberg, M. W.; Santos, L. M. Vitamin D3 induces IDO(+) tolerogenic DCs and enhances Treg, reducing the severity of EAE. CNS Neurosci. Ther., 2013, 19 (4), 269-277.
99. Urry, Z.; Chambers, E. S.; Xystrakis, E.; Dimeloe, S.; Richards, D. F.; Gabrysova, L.; Christensen, J.; Gupta, A.; Saglani, S.; Bush, A.; O'Garra, A.; Brown, Z.; Hawrylowicz, C. M. The role of 1alpha,25-Dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3+ and IL-10+ CD4+ T cells. Eur. J. Immunol., 2012, 42 (10), 2697-2708.
100. Ardalan, M. R.; Maljaei, H.; Shoja, M. M.; Piri, A. R.; Khosroshahi, H. T.; Noshad, H.; Argani, H. Calcitriol started in the donor, expands the population of CD4+CD25+ T cells in renal transplant recipients. Transplant Proc., 2007, 39 (4), 951-953.
101. Day, Y. J.; Huang, L.; Ye, H.; Li, L.; Linden, J.; Okusa, M. D. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J. Immunol., 2006, 176 (5), 3108-3114.
102. Burne-Taney, M. J.; Ascon, D. B.; Daniels, F.; Racusen, L.; Baldwin, W.; Rabb, H. B Cell deficiency confers protection from renal ischemia reperfusion injury. J. Immunol., 2003, 171 (6), 3210-3215.
103. Burne, M. J.; Daniels, F.; El Ghandour, A.; Mauiyyedi, S.; Colvin, R. B.; O'Donnell, M. P.; Rabb, H. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J. Clin. Invest., 2001, 108 (9), 1283-1290.
104. Day, Y. J.; Huang, L.; Ye, H.; Linden, J.; Okusa, M. D. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am. J. Physiol. Renal Physiol., 2005, 288 (4), F722-731.
105. Li, L.; Huang, L.; Sung, S. S.; Lobo, P. I.; Brown, M. G.; Gregg, R. K.; Engelhard, V. H.; Okusa, M. D. NKT cell activation mediates neutrophil IFN-gamma production and renal ischemia-reperfusion injury. J. Immunol., 2007, 178 (9), 5899-5911.
106. Kankova, M.; Luini, W.; Pedrazzoni, M.; Riganti, F.; Sironi, M.; Bottazzi, B.; Mantovani, A.; Vecchi, A. Impairment of cytokine production in mice fed a vitamin D3-deficient diet. Immunology, 1991, 73 (4), 466-471.
107. Kim, Y. O.; Li, C.; Sun, B. K.; Kim, J. S.; Lim, S. W.; Choi, B. S.; Kim, Y. S.; Kim, J.; Bang, B. K.; Yang, C. W. Preconditioning with 1,25-dihydroxyvitamin D3 protects against subsequent ischemia-reperfusion injury in the rat kidney. Nephron. Exp. Nephrol., 2005, 100 (2), e85-94.
108. Carthy, E. P.; Yamashita, W.; Hsu, A.; Ooi, B. S. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension, 1989, 13 (6 Pt 2), 954-959.
109. Jablonski, K. L.; Chonchol, M.; Pierce, G. L.; Walker, A. E.; Seals, D. R. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension, 2011, 57 (1), 63-69.
110. London, G. M.; Guerin, A. P.; Verbeke, F. H.; Pannier, B.; Boutouyrie, P.; Marchais, S. J.; Metivier, F. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J. Am. Soc. Nephrol., 2007, 18 (2), 613-620.
111. Levin, A.; Li, Y. C. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int., 2005, 68 (5), 1973-1981.
112. Sugden, J. A.; Davies, J. I.; Witham, M. D.; Morris, A. D.; Struthers, A. D. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet. Med., 2008, 25 (3), 320-325.
113. Tarcin, O.; Yavuz, D. G.; Ozben, B.; Telli, A.; Ogunc, A. V.; Yuksel, M.; Toprak, A.; Yazici, D.; Sancak, S.; Deyneli, O.; Akalin, S. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J. Clin. Endocrinol. Metab., 2009, 94 (10), 4023-4030.
114. Park, J. W.; Cho, J. W.; Joo, S. Y.; Kim, C. S.; Choi, J. S.; Bae, E. H.; Ma, S. K.; Kim, S. H.; Lee, J.; Kim, S. W. Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation. Eur. J. Pharmacol., 2012, 683 (1-3), 301-309.
115. Chen, J.; John, R.; Richardson, J. A.; Shelton, J. M.; Zhou, X. J.; Wang, Y.; Wu, Q. Q.; Hartono, J. R.; Winterberg, P. D.; Lu, C. Y. Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury. Kidney Int., 2011, 79 (3), 288-299.
116. Kelly, K. J.; Williams, W. W. Jr.; Colvin, R. B.; Meehan, S. M.; Springer, T. A.; Gutierrez-Ramos, J. C.; Bonventre, J. V. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J. Clin. Invest., 1996, 97 (4), 1056-1063.
117. Bonizzi, G.; Karin, M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol., 2004, 25 (6), 280-288.
118. Sanz, A. B.; Sanchez-Nino, M. D.; Izquierdo, M. C.; Jakubowski, A.; Justo, P.; Blanco-Colio, L. M.; Ruiz-Ortega, M.; Selgas, R.; Egido, J.; Ortiz, A. TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS One, 2010, 5 (1), e8955.
119. Loverre, A.; Ditonno, P.; Crovace, A.; Gesualdo, L.; Ranieri, E.; Pontrelli, P.; Stallone, G.; Infante, B.; Schena, A.; Di Paolo, S.; Capobianco, C.; Ursi, M.; Palazzo, S.; Battaglia, M.; Selvaggi, F. P.; Schena, F. P.; Grandaliano, G. Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by rapamycin. J. Am. Soc. Nephrol., 2004, 15 (10), 2675-2686.
120. Sun, J.; Kong, J.; Duan, Y.; Szeto, F. L.; Liao, A.; Madara, J. L.; Li, Y. C. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am. J. Physiol. Endocrinol. Metab., 2006, 291 (2), E315-22.
121. Tan, X.; Wen, X.; Liu, Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J. Am. Soc. Nephrol., 2008, 19 (9), 1741-1752.
122. Suzuki, Y.; Ichiyama, T.; Ohsaki, A.; Hasegawa, S.; Shiraishi, M.; Furukawa, S. Anti-inflammatory effect of 1alpha,25-Dihydroxyvitamin D(3) in human coronary arterial endothelial cells: Implication for the treatment of Kawasaki disease. J. Steroid Biochem. Mol. Biol., 2009, 113 (1-2), 134-138.
123. Hoffmann, S.; Podlich, D.; Hahnel, B.; Kriz, W.; Gretz, N. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J. Am. Soc. Nephrol., 2004, 15 (6), 1475-1487.
124. Zhou, C.; Lu, F.; Cao, K.; Xu, D.; Goltzman, D.; Miao, D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int., 2008, 74 (2), 170-179.